Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVO-BRAIN: Upfront SRT + Ivonescimab + Chemotherapy vs Ivonescimab + Chemotherapy in NSCLC with Brain Metastases
NCT07234877Phase 2Not yet recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Nov 2026
- Primary completion
- Jan 2032
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of ivonescimab in non-small cell lung cancer (NSCLC), sponsored by European Organisation for Research and Treatment of Cancer. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07234877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07234877.